Definition
What does pharma grade mean?
Nothing defined. No regulation fixes the phrase pharma grade, no body awards it, and no test confirms it. At its most generous it means the material meets a pharmacopoeial monograph — which, for every cannabinoid discussed on this site, does not exist. Treat it as a prompt rather than a claim: the useful question is what the specification actually says, because a purchase order written against pharma grade has nothing behind it to arbitrate if the material disappoints.
Why does the phrase persist if it means nothing?
Because it is doing a real job badly. A buyer using it is asking whether material is good enough for a regulated product, which is a fair question with no short way to ask it. A seller using it is answering yes without committing to anything, which is why it survives on datasheets.
The phrase also travels between industries where it does carry local meaning — in solvents and excipients, pharma grade often points at a USP or Ph. Eur. monograph that genuinely exists. Borrowed into cannabinoids, where no such monograph has been written, it arrives empty.
What should I ask for instead?
The specification. Five lines, each one checkable when the drum arrives and each one arguable if it disappoints, which an adjective never is.
- Identity method: HPLC against what reference, and can the method separate the close analogues?
- Assay basis: percent by weight or by area, and dried or as-is?
- Impurity list: which impurities are reported, at what threshold, and which are qualified?
- Residuals: solvents, heavy metals, pesticides — with the panel named, not implied.
- Storage and retest: the condition on the certificate, and the date the assay is good until.
Is ≥99.9% pharma grade?
It is a purity figure, and a good one. It is not a grade, because grade describes a regime and purity describes a number.
The distinction has teeth. An API is judged on its characterised impurity profile — what the remaining fraction is, whether each component is identified, and whether the ones above threshold are toxicologically qualified. A material can read 99.9% and still have an uncharacterised 0.1% that no regulator would accept. Purity is necessary. It was never sufficient.
What does Peregrine say about its own material?
That it is research-grade isolate, specified at ≥99.9%, with identity by HPLC against a qualified reference standard, assay as percent by weight, and a certificate for the lot that ships with the material. Sold as an ingredient, with no structure, function or disease claim attached.
The phrase pharma grade appears nowhere on a Peregrine certificate, and that is deliberate. Peregrine is working to supply all of it — API-grade material, certified standards and GMP-declared volume — at research and industrial scale worldwide, through its own patented synthesis process.
Questions
Is pharma grade a regulated term?
No. No regulation defines it, no body awards it, and no test confirms it. In industries with pharmacopoeial monographs it often points at one; for cannabinoids no such monograph exists.
What is the difference between pharma grade and research grade?
Research grade usually means identity and assay on a certificate, sold as an ingredient. Pharma grade means whatever the seller intends by it, which is why only the first of the two can be written into a purchase order and enforced.
Is pharmaceutical-grade CBG available?
Not in any sense that would survive a question. CBG has no pharmacopoeial monograph, so there is no standard for the phrase to point at. High-purity research-grade CBG isolate is available and is a different, honest claim.
What purity does Peregrine specify?
≥99.9% on the named isolates, with identity by HPLC and assay as percent by weight, reported on a certificate for the lot that ships with the material.
Does high purity make a compound suitable for a drug product?
Not on its own. An API is judged on its characterised impurity profile and the manufacturing regime behind it, so an uncharacterised remaining fraction can disqualify material that reads very pure.
Sources
- 21 CFR 210.3(b)(7)FDA's definition of an active ingredient
- ICH Q7Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, Step 4, 2000
- ICH Q3A(R2)Impurities in New Drug Substances, Step 4, 2006
The vocabulary
- What is an API (active pharmaceutical ingredient)?The regulatory definition, the five things it actually requires, and why a purity figure is not one of them.
- API grade vs research grade: what actually changesThe molecule is the same. What differs is how much of its history is documented, and who answers for it.
- Where do I buy a cannabinoid reference standard?Who actually sells them, what the certificate must say, and why ISO 17034 and 17025 are not interchangeable.
- GMP ingredients: which GMP, and what each one coversFour unrelated regimes share the word. Which certificate means what, and the three questions that settle a claim.
- How do you qualify a cannabinoid API supplier?Directory listings promise DMF and CEP against compounds that can hold neither. The questions that separate a manufacturer from a broker.
By compound
- CBG — API, standard and GMP statusNo approved drug uses CBG, no USP standard exists, and what GMP CBG usually means.
- CBGA — API, standard and GMP statusThe precursor acid: no monograph, no drug programme, and what its stability question is.
- CBGV — API, standard and GMP statusThe varin branch precursor: scarce, campaign-based, no monograph.
- CBDV — API, standard and GMP statusThe one with real clinical history — and what missing an endpoint does and does not change.
- THCV — API, standard and GMP statusWhere today's purity falls short of an API bar, stated plainly.
- CBN — API, standard and GMP statusThe only one with any pharmacopoeial presence — and why an impurity limit is not a standard.
- Cannflavin A — API, standard and GMP statusA prenylated flavone, not a cannabinoid: preclinical, milligram-scale, no bulk supply anywhere.